Cancer Care

Our comprehensive, nationally recognized oncology program offers a full continuum of services, from diagnosis through treatment and recovery. While the road may be long, it need not be far. JFK Medical Center is committed to providing exceptional quality cancer care where you need it most, in your own community.

JFK Medical Center is dedicated to advancing knowledge and enhancing care by creating a collaborative environment focused on the prevention, detection, and treatment of cancer to improve quality of life for patients and survivors. We offer a full complement of comprehensive diagnostic and treatment services – advanced, state of the art diagnostic equipment, pathology, surgery, medical oncology, radiation oncology, stereotactic radiosurgery, and investigational clinical trials. In 2014 JFK completely renovated our Inpatient Oncology unit, which includes 15 beds and an infusion unit. The renovation not only provided for two additional private rooms, but also ensured that all the rooms were more spacious, comfortable and welcoming not only for the patients, but their families, as well. Our Outpatient Infusion Unit is a ten chair unit. It is an innovative, state-of-the-art facility where you can receive intravenous infusions and therapeutic injections in a safe, professional and comfortable environment. Infusion Unit is open seven days a week, from 8am to 5pm.

The JFK Neuroscience Institute and The Breast Center are two premier service programs offered at JFK. JFK Medical Center is also an affiliate of the Rutgers Cancer Institute of New Jersey which provides the patients an opportunity to participate in clinical trials. And for a holistic comprehensive approach to patient care, JFK provides complimentary therapies to support the diverse needs of cancer patients, including oncology certified nursing care, nutritional care, discharge planning, outpatient services, counseling, and palliative and hospice care.

Prevention and Early Detection

Cancer screenings and early detection are the keys to successful outcomes in cancer care. Advanced radiologic technology and nuclear medicine at JFK Medical Center and the Breast Center are linked through a digital picture archiving and communications system (PACS) that expedites test results and ensures the quickest path to effective therapy.

Support Services

Because of the comprehensive cancer services available at JFK, the need for patients and their families to travel out of central New Jersey for state of the art cancer treatment is eliminated. Patients and their families can take comfort in knowing that knowledgeable cancer experts are available at JFK, close to home.

Healing and Recovery

The cancer journey extends well beyond treatment for both patients and their families, as they forge new avenues of surviving their disease and cancer experience. Right from the start, experienced, compassionate counselors are available to provide one-on-one guidance and support as patients cope with the psychological and emotional aspects of their illness, therapies and recovery. JFK Medical Center addresses these needs with a continuum of services to promote healing and hope for the future.

DLBCL: InCB 50465-202 – A phase 2 multicenter international open label safety and efficacy study of INCB 050465 in subjects with relapsed or refractory diffused large B cell lymphoma

Follicular/Marginal Zone/or Mantle Cell Lymphoma:

• Celgene CC-5013-NHL-008 – Magnify – A phase 3 B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide single agent maintenance vs rituxamab maintenance in subjects with relapsed/refractory follicular, marginal zone or mangle cell lymphoma
• INCB 50465-203 – A phase 2 multicenter open label study of INCB050465, a P13K inhibitor in relapsed or refractory follicular lymphoma
• INCB 50465-204 – Phase 2 open label 2 cohort study of INCB 050465 a P13K inhibitor in subjects with relapsed or refractory marginal zone lymphoma with or without prior exposure to a BTK inhibitor
• INCB 50465-205 – A phase 2 open label 2 cohort multicenter study of INCB 50465 a P14k inhibitor in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor
• Acerta ACE-LY-003 – Phase 1b/2 open label study of alcalabrutinib alone or in combination with rituxan in subjects with indolent b-cell NHL

Metastatic Disease: Horizon BCBS – Observational GPS study for patient with patients who have Horizon BCBS insurance and metastatic disease

Multiple Myeloma: Millenium C16021 – A phase 3 randomized, placebo-controlled double blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant

Ovarian Cancer: Astrazenca light D018161003 – Non randomized open label phase 2 study to access oliparib tablets as a treatment for subjects with different HRD tumor status and with platinum sensitive, relapsed, high grade or high grade endometriod ovarian, fallopian tube of primary periotoneal cancer that have received at least 1 prior line of chemo

Pancreatic:  CanStem111P – Phase 3 open label randomized, study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemzar (arm 1) vs nab-paclitaxel with gemzar (arm 2) in metastatic disease